A higher dose of Wegovy has received final regulatory clearance in the EU, marking a significant step for obesity treatment. The approval allows physicians to prescribe a weekly 7.2 mg dose, administered as Slow release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double blind, placebo controlled, randomised trial The Lancet HIV How Long Does Phentermine Stay in Your System? FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity Mega Doctor News Can you switch from Ozempic to Mounjaro? Mounjaro weight loss UK